IN8bio (INAB) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic focus and pipeline updates

• Shifted corporate strategy to prioritize INB-100 for leukemia, pausing other programs to conserve resources.

• INB-100 uses donor-derived gamma delta T cells to prevent relapse in post-transplant leukemia patients, showing 100% remission at one year in early studies.

• INB-200 for recurrent GBM showed promising results but was suspended due to challenging funding environment and investor feedback.

• Preclinical assets, including non-signaling CARs and iPSC-derived gamma delta T cells, are being considered for partnerships.

• Over 50% reduction in workforce to extend cash runway and focus on core programs.

Clinical data and development plans

• INB-100 demonstrated durable remissions in AML patients, with some remaining relapse-free for over four years.

• Study expansion planned to 20-25 patients to address investor concerns about sample size and risk.

• Next clinical data update expected at ASH, with additional retrospective and prospective control data to be presented.

• No significant safety issues observed with INB-100, including no GVHD, cytokine release syndrome, or neurotoxicity.

• Ongoing efforts to enroll standard-of-care controls and conduct meta-analyses for further validation.

Market environment and financial position

• Biotech and pharma sectors face significant funding challenges, impacting development timelines and strategic decisions.

• Last reported cash position was over CAD 10 million, expected to last into early next year.

• Actively seeking partnerships and investor support to advance pipeline and registrational trials.

• Internal manufacturing capabilities maintained to support ongoing and future projects.

• Industry-wide layoffs and program discontinuations noted as context for current strategy.